Moody Aldrich Partners LLC Sells 33,086 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Moody Aldrich Partners LLC reduced its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 15.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 182,571 shares of the biopharmaceutical company's stock after selling 33,086 shares during the period. Moody Aldrich Partners LLC owned approximately 0.15% of Catalyst Pharmaceuticals worth $4,427,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Principal Financial Group Inc. raised its holdings in Catalyst Pharmaceuticals by 2.8% in the 1st quarter. Principal Financial Group Inc. now owns 617,506 shares of the biopharmaceutical company's stock valued at $14,975,000 after buying an additional 17,018 shares during the period. Meritage Portfolio Management raised its holdings in Catalyst Pharmaceuticals by 4.2% in the 1st quarter. Meritage Portfolio Management now owns 48,039 shares of the biopharmaceutical company's stock valued at $1,165,000 after buying an additional 1,949 shares during the period. Smallwood Wealth Investment Management LLC purchased a new stake in Catalyst Pharmaceuticals in the 1st quarter valued at about $182,000. Illinois Municipal Retirement Fund raised its holdings in Catalyst Pharmaceuticals by 1.6% in the 1st quarter. Illinois Municipal Retirement Fund now owns 60,638 shares of the biopharmaceutical company's stock valued at $1,470,000 after buying an additional 929 shares during the period. Finally, Spire Wealth Management raised its holdings in Catalyst Pharmaceuticals by 27.7% in the 1st quarter. Spire Wealth Management now owns 18,429 shares of the biopharmaceutical company's stock valued at $447,000 after buying an additional 4,000 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Price Performance

NASDAQ:CPRX traded down $0.51 during midday trading on Monday, reaching $20.95. 1,161,065 shares of the company traded hands, compared to its average volume of 1,119,507. Catalyst Pharmaceuticals, Inc. has a twelve month low of $15.19 and a twelve month high of $26.58. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of 13.34, a price-to-earnings-growth ratio of 0.87 and a beta of 0.66. The company has a fifty day moving average price of $23.73 and a 200 day moving average price of $22.91.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Six research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $32.83.

Insider Buying and Selling at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 44,000 shares of the business's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total transaction of $1,039,720.00. Following the completion of the transaction, the insider owned 68,873 shares of the company's stock, valued at approximately $1,627,468.99. The trade was a 38.98% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Preethi Sundaram sold 1,600 shares of the business's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $26.42, for a total value of $42,272.00. Following the transaction, the insider directly owned 41,081 shares of the company's stock, valued at $1,085,360.02. This represents a 3.75% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 247,924 shares of company stock valued at $5,879,369. 10.40% of the stock is owned by insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.